EVM
VKTX icon

Eaton Vance Management’s Viking Therapeutics VKTX Stock Holding History

Eaton Vance Management’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-100
Closed – – 2884
2021
Q3 		$0 Sell
100
-47
-32% -$290 ﹤0.01% 2705
2021
Q2 		$1K Buy
+147
New +$873 ﹤0.01% 2778

Other funds holding VKTX

ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Eaton Vance Management's VKTX Position: Q4 2021 in Review

Eaton Vance Management sold out of Viking Therapeutics (VKTX) in Q4 2021, closing a stake of 100 shares.

Eaton Vance Management first reported a position in VKTX in Q2 2021 and held it in 2 quarters. The position peaked at $1K in Q2 2021. 140 funds tracked by Wall St. Rank hold VKTX as of Q4 2021.

  • Eaton Vance Management reported no remaining Viking Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Eaton Vance Management sold 100 Viking Therapeutics shares in Q4 2021.
  • Eaton Vance Management first reported a position in Viking Therapeutics in Q2 2021 and held it in 2 quarters.
  • Eaton Vance Management's Viking Therapeutics position peaked at $1K in Q2 2021.
  • 140 funds tracked by Wall St. Rank held Viking Therapeutics as of Q4 2021.

Based on Eaton Vance Management's 13F filing for Q4 2021, filed 14 Feb 2022.